The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S(2023) Efficient chimeric antigen receptor (CAR) targeting of a central epitope of CD22 J Biol Chem, 104883(in press) DOI 10.1016/j.jbc.2023.104883, PubMed 37269947
Svendsen VG, Stavseth MR, Skardhamar T, Bukten A(2023) Psychiatric morbidity among women in Norwegian prisons, 2010-2019: a register-based study BMC Psychiatry, 23(1), 390 DOI 10.1186/s12888-023-04886-7, PubMed 37268924
Mikalsen LTG, Kvassheim M, Stokke C(2023) Optimized SPECT Imaging of 224Ra α-Particle Therapy by 212Pb Photon Emissions J Nucl Med(in press) DOI 10.2967/jnumed.122.264455, PubMed 37268424